Wall Street’s Stark Divide Over UnitedHealth Shares

A surprising consensus is emerging among major financial institutions regarding UnitedHealth Group, even as the healthcare giant’s stock performance tells a contrasting story. Despite significant price target upgrades from prominent investment banks, shares of UnitedHealth declined in recent trading, creating a puzzling market dynamic.

Conflicting Signals from the Market

UnitedHealth shares closed at $356.67, registering a 1.24% decline that underperformed the broader S&P 500 index. This downward movement occurred simultaneously with overwhelmingly positive analyst actions, presenting investors with conflicting signals about the company’s near-term prospects.

Jefferies’ Dramatic Revision

In the most striking development, Jefferies Financial Group implemented a substantial increase to their price target, raising it from $317 to $409 per share. This adjustment represents a significant 29% upward revision, reflecting considerable confidence in the healthcare conglomerate’s recovery potential.

The firm maintained its buy recommendation while establishing a new target that suggests substantial upside from current trading levels. Jefferies appears to be positioning for a major turnaround in UnitedHealth’s operational and market performance.

Goldman Sachs Initiates Coverage with Bullish Stance

Separately, Goldman Sachs entered the coverage landscape with an optimistic outlook. Analyst Scott Fidel established coverage with a buy recommendation and a $406 price target. The investment bank’s bullish thesis centers primarily on anticipated margin improvements within UnitedHealth’s Medicare Advantage segment, with meaningful recovery projected beginning in 2026.

Goldman’s analysts identified several key factors supporting their positive assessment:

Should investors sell immediately? Or is it worth buying Unitedhealth?

• Projected recovery in Medicare Advantage profit margins
• New management implementing more conservative pricing approaches
• Business practice reviews intended to reassure shareholders
• Strategic positioning to capitalize on industry-wide recovery

Upcoming Earnings Report Creates Uncertainty

Investor attention now turns to the quarterly earnings announcement scheduled for October 28. Analyst expectations reveal a mixed picture, with earnings per share forecasts pointing toward $2.84—representing a dramatic 60.28% year-over-year decline.

Revenue projections appear more favorable, with experts anticipating $113.38 billion, which would constitute a 12.46% annual increase. The critical question remains whether UnitedHealth can surpass the pessimistic profit forecasts.

Medicare Advantage: The Central Recovery Narrative

Both Goldman Sachs and industry observers identify Medicare Advantage as the pivotal element in UnitedHealth’s potential resurgence. This business segment has encountered substantial underwriting challenges that significantly impacted the company’s projected 2025 performance.

Goldman characterized the current environment as the sector’s most severe underwriting crisis in over fifteen years. Paradoxically, the bank identifies this troubled segment as offering the greatest improvement potential beginning in 2026, forming the foundation for their optimistic price targets.